AGIC Capital Completes Investment into Eulitha AG
European-Asian private equity firm AGIC Capital today announces that an investment fund under its management has entered into a set of transaction documents in respect of an undisclosed amount into Eulitha AG, a specialized technology provider of non-contact Nano-UV-Lithography equipment and services.
Founded in 2006 in Switzerland, Eulitha offers unique and cost-efficient non-contact, high-resolution photolithography systems and customized patterning services for a wide range of applications, including DFB/DBR Lasers, AR/VR, Telecommunications, Optical Components and Bio Sensors/Chips. Eulitha’s proprietary PHABLE™ technology is considered to be a preferable option to traditional nanoimprint technology due to lower costs, higher throughput, better consistency, longer mask lifetime and compatibility with non-flat substrates.
AGIC Capital was attracted to Eulitha’s strong positioning as a unique and innovative technology provider in fast-growing markets including AR/VR (Augmented and Virtual Reality) industries and its promising commercialization pipeline backed by strong R&D abilities. AGIC Capital will work closely with the management team to support Eulitha’s international development in particularly the Asia Pacific region and use resources with large industrial players to help the company increase sales and customers.
Heiko von Dewitz, Partner of AGIC Capital in Europe, said: “AGIC Capital believes Eulitha is well poised to gain substantially from the underlying market trends favoring its proprietary equipment and process technology solutions. We are very pleased to have made this investment and will work with the Eulitha management team to scale up the business and accelerate its growth across a variety of industries.”
Dr. Harun Solak, CEO and Co-founder of Eulitha, said: “We are delighted to have AGIC Capital on board on our journey to become a global leader in offering lithography solutions to the growing photonics industries. With this investment Eulitha will be significantly expanding its resources, both financially and in terms of its market reach, to further develop and market its unique photolithography equipment and associated technologies.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220704005072/en/
Contact information
For more information, please visit www.agic-group.com or contact:
AGIC Capital
Heiko Von Dewitz
Email: contactus@agic-group.com
T: +49 89235135 62-0
About Business Wire
Business WireSubscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LumiThera Receives Notice of Award for National Eye Institute Grant to Support a 3 rd Year Extension to LIGHTSITE III, the U.S. Multi-Center Clinical Trial for Treating Dry Age-Related Macular Degeneration27.9.2023 17:28:00 CEST | Press release
LumiThera Inc., a medical device company commercializing a photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it is a recipient of a small business innovative research (SBIR) phase II grant from the National Institute of Health (NIH) and the division of the National Eye Institute (NEI) of up to $2.3M in funding over two years. The NIH/NEI grant supports an open-label human clinical trial in U.S. intermediate dry age-related macular degeneration (dry AMD) subjects that participated in the pivotal LIGHTSITE III trial. LIGHTSITE IIIB will treat patients for 4 rounds of treatment over fourteen months. Sham patients in the previous study will be able to cross over and begin PBM treatment. The LIGHTSITE IIIB extension trial follows the successfully completed LIGHTSITE III trial, which showed a sustained, mean increase in best corrected vision acuity (BCVA) letter score of >5.0 letters from baseline at the 13- and 24-month timepoints (p < 0.0001) using the Co
XPENG Shipped 750 Vehicles to Israel, Coming Closer to G9 and P7's Launch in October27.9.2023 16:02:00 CEST | Press release
XPENG (NYSE: XPEV and HKEX: 9868), a leading smart electric vehicle company, today announced that it has shipped 750 vehicles for the Israeli market, marking this the largest single batch of export this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230927239985/en/ Hey XPENG, navigate to Israel! (Photo: Business Wire) The batch left the Guangzhou Port after the conclusion of a ceremony that included local customs officials and port representatives. “We're very grateful for the support of our partners and the local customs officials as we take a significant step toward launching in Israel," said Eric Xu, VP of International Markets, XPENG. "With the help of our local partner, Freesbe, the launch of our smart EVs is just around the corner—and we can't wait." The two models expected to be available in Israel, XPENG P7 and XPENG G9, have also been adapted to meet the preferences of local drivers. Together with Freesbe, wi
SoftServe Debuts Sage, the AI Pathfinder, at Money20/2027.9.2023 15:03:00 CEST | Press release
SoftServe, a premier IT consulting and digital services provider, will debut Sage, the AI Pathfinder, a financial intelligence consultant powered by Generative AI using NVIDIA Avatar Cloud Engine (ACE), at Money20/20 USA. Attendees can interact with the immersive experience offering financial decisioning and education at booth #13117 starting Oct. 22. Sage, the AI Pathfinder, is enhanced with a customized ChatGPT module combined with visual avatars and dynamic content. It features real-time information processing for interactive decision-making to offer personalized financial recommendations. Financial wellness is a struggle for 58% of Americans living paycheck to paycheck. Only 51% have more emergency savings than credit card debt. “A lack of financial literacy is a big part of this problematic equation,” said Filippa Noghani, AVP of Marketing at SoftServe and NYC Fintech Women Board Member. “Generative AI technologies create promising educational opportunities, especially for millenn
PPG’s COLORFUL COMMUNITIES program marks 500th project with makeover at Carnegie Science Center in Pittsburgh27.9.2023 15:00:00 CEST | Press release
PPG (NYSE:PPG) today announced the completion of its 500th COLORFUL COMMUNITIES® project – a colorful and transformational makeover at Carnegie Science Center in Pittsburgh. More than 80 volunteers marked the milestone by creating science-themed murals and applying fresh paint and color in learning spaces around the center. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230927335327/en/ PPG volunteers completed the 500th COLORFUL COMMUNITIES® project at the Carnegie Science Center in Pittsburgh, kicking off a month-long, worldwide celebration. (Photo: Business Wire) Completion of the 500th Colorful Communities project kicks off a month-long, worldwide celebration of the volunteers, community partners and individuals who have helped to bring color and brightness to PPG communities. From China to the Netherlands, additional projects are planned across the world to mark the milestone. “When we launched the Colorful Communities
Syntropy Announces Collaboration with Evidium to Advance Data-Centric Healthcare27.9.2023 15:00:00 CEST | Press release
Today, Syntropy, a partnership between Merck and Palantir Technologies Inc., announced a collaboration with Evidium, a developer of a healthcare platform that enables AI use in a responsible, reliable, and referenceable manner. The organizations will make end-to-end medical knowledge more computational and improve data quality for clinical research and practice. The coalition will be facilitated through Syntropy’s secure data collaboration platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230927301328/en/ Evidium’s Referenced AI platform will play a key role in transforming narrative-form information into AI-ready knowledge at the elemental level. This will allow clinical data to be disseminated and utilized with unprecedented scale and precision. Syntropy’s secure, collaborative ecosystem will enable researchers to review high-quality data, share insights, and apply their findings to clinical trials, helping to gener
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom